BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 18, 2026
Home » Topics » Medical technology

Medical technology
Medical technology RSS Feed RSS

HIT roundup: Jericho to explore patient control over shared records

Feb. 25, 2013

Med-Tech Notes

Feb. 25, 2013

People in the News

Feb. 25, 2013

MDD's Neurology Extra

Feb. 25, 2013

SEMDA 2013: Shuren says FDA addressing concerns with review process

Feb. 25, 2013
By Omar Ford
ATLANTA — For years medical device makers have fired off concerns and criticisms of the FDA's regulatory process – at times going so far as to call it unpredictable. Last week, during the Southeastern Medical Device Association's (SEMDA; Norcross, Georgia) annual conference held at the Georgia Institute of Technology Global Learning Center (Atlanta), med-tech firms got the chance to hear directly from the Center for Devices and Radiological Health's (CDRH) director – Jeffrey Shuren.
Read More

State of the Spine Industry: Evolution, fusion, and PODs head the list of concerns

Feb. 25, 2013
By Robert Kimball

Forget optimism, worldwide pressures continue in 2013

Feb. 25, 2013
By Amanda Pedersen

SEMDA conference did not disappoint

Feb. 22, 2013
By Omar Ford
Earlier this week, I had the privilege of attending the Southeastern Medical Device Association's (SEMDA) annual conference. It was a tremendous opportunity to meet the players in the med-tech space that are located close to the office where  Medical Device Daily is published. I would have to say that this conference did not disappoint. The presentations were lively; the speakers were great and the topics were very relevant to the med-tech industry. Perhaps one of my most favorite speakers was Jon Ellenthal, a partner and President of TEDMED, a company focused on innovation and breakthrough thinking across all of health...
Read More

Washington roundup: BPC says leave FDA out of regulation of healthcare IT

Feb. 22, 2013
By Mark McCarty

SEMDA 2013: A CEO's journey is roller coaster ride of successes and failures

Feb. 22, 2013
By Omar Ford
ATLANTA — Just what does it take to be a CEO of a successful med-tech startup? What does the journey look like for a CEO that has made it through the process of taking an idea and building a product and business around it? Those questions were answered during the CEO Roundtable, one of the more popular sessions at the Southeastern Medical Device Conference (SEMDA; Norcross Georgia) on Wednesday.
Read More
Previous 1 2 … 3617 3618 3619 3620 3621 3622 3623 3624 3625 … 10247 10248 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 18, 2026.
  • DNA and genome editing illustration

    ASGCT 2026: Directed evolution in gene therapy

    BioWorld
    Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • Doctor with brain illustration, businessman with dollar sign illustration

    Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal

    BioWorld
    Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
  • Illustration of tau accumulating in a neuron cell.

    Biogen AD drug shows tau, cognition benefit, despite trial miss

    BioWorld
    Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing